The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Diurnal blood pressure in patients with mild‐to‐moderate hypertension treated with once‐daily benazepril hydrochloride
This study evaluated the blood pressure effects of administration of once daily oral benazepril hydrochloride , a new angiotensin‐converting enzyme ( ACE ) inhibitor , for mild‐to‐moderate hypertension . After a 2 to 4 week placebo baseline period , patients with diastolic blood pressure between 95 and 114 mm Hg , were r and omized to receive either placebo or benazepril hydrochloride , 5 , 10 , 20 , or 40 mg , once daily in double‐blind fashion for 28 days . Blood pressure was measured predose and at 1 , 2 , 3 , 4 , 6 , 8 , 12 , 16 , 20 , and 24 hours after the dose during inpatient observation days at the end of the placebo baseline period , and on the first and last day of the double‐blind treatment period ; and 24 hours after the dose at weekly outpatient visits . All doses of benazepril hydrochloride result ed in clinical ly important reductions in diastolic and systolic blood pressures that lasted between 12 and 24 hours after both the first dose , and following the last dose after 4 weeks of treatment . The findings indicate that benazepril hydrochloride may be clinical ly useful as once‐daily monotherapy in many patients with hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .